HomeCompareSUB vs NOBL

SUB vs NOBL: Dividend Comparison 2026

SUB yields 2.47% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SUB wins by $471.00 in total portfolio value
10 years
SUB
SUB
● Live price
2.47%
Share price
$106.50
Annual div
$2.63
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$289.13
Full SUB calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SUB vs NOBL

📍 SUB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSUBNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SUB + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SUB pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SUB
Annual income on $10K today (after 15% tax)
$209.59/yr
After 10yr DRIP, annual income (after tax)
$245.76/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SUB beats the other by $33.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SUB + NOBL for your $10,000?

SUB: 50%NOBL: 50%
100% NOBL50/50100% SUB
Portfolio after 10yr
$23.1K
Annual income
$269.46/yr
Blended yield
1.17%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SUB buys
0
NOBL buys
0
No recent congressional trades found for SUB or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSUBNOBL
Forward yield2.47%2.17%
Annual dividend / share$2.63$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$23.4K$22.9K
Annual income after 10y$289.13$249.78
Total dividends collected$2.7K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SUB vs NOBL ($10,000, DRIP)

YearSUB PortfolioSUB Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$10,947$246.58$10,917$217.08+$30.00SUB
2$11,965$252.26$11,903$221.48+$62.00SUB
3$13,060$257.69$12,962$225.68+$98.00SUB
4$14,237$262.88$14,099$229.68+$138.00SUB
5$15,502$267.83$15,319$233.49+$183.00SUB
6$16,860$272.54$16,628$237.10+$232.00SUB
7$18,317$277.01$18,033$240.53+$284.00SUB
8$19,880$281.27$19,539$243.78+$341.00SUB
9$21,557$285.30$21,154$246.86+$403.00SUB
10$23,355$289.13$22,884$249.78+$471.00SUB

SUB vs NOBL: Complete Analysis 2026

SUBStock

The iShares Short-Term National Muni Bond ETF seeks to track the investment results of an index composed of investment-grade U.S. municipal bonds with remaining maturities between one month and five years.

Full SUB Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SUB vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SUB vs SCHDSUB vs JEPISUB vs OSUB vs KOSUB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.